NFE2L2 and breast carcinoma: The mechanistic insights on MCF-7 breast cancer cells showed that HBXIP reduced the ROS levels by promoting nuclear NRF2 accumulation and the subsequent transactivation of NRF2-dependent target genes such as NAD(P)H dehydrogenase-1 (NQO1), glutamate-cysteine ligase catalytic and modifier subunits (GCLC and GCLM) and AKR1C1.